FASLG and neoplasm: To test the suppressive effect of FasL+PD‐L2+ neutrophils on tumor‐specific CD8+ T‐cell immunity in vivo, we treated TTCS‐conditioned neutrophils (TCN) with FasL and/or PD‐L2 blocking antibody or control IgG and then injected them together with autologous tumor‐specific CD8+ T cells into our established human NOD/SCID mice bearing SGC7901‐derived GC.